A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial

Archives of Cardiovascular Diseases

Volumn 105, Issue 11, 2012, Pages 587-592

  Oberhänsli, Markus ^a   Lehner, Cédric ^a   Puricel, Serban ^a   Lehmann, Sonja ^a   Togni, Mario ^a   Stauffer, Jean Christophe ^a   Baeriswyl, Gérard ^a   Goy, Jean Jacques ^a   Cook, Stéphane ^a  

^a Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

Antiplatelet; Aspirin; Clopidogrel; Percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; CLOPIDOGREL MEPHA; CLOPIDOGREL SANDOZ; GENERIC DRUG; PRASUGREL; UNCLASSIFIED DRUG;

ADENOSINE DIPHOSPHATE TEST; AGED; ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLATELET REACTIVITY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; STENTS; THERAPEUTIC EQUIVALENCY; THIOPHENES; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84869489876     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2012.06.001     Document Type: Article

References (16)

1. P.J. Casterella, and J.E. Tcheng Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions Am Heart J 155 2008 781 790
2. S.B. King 3rd., S.C. Smith Jr., and J.W. Hirshfeld Jr. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on behalf of the 2005 Writing Committee Circulation 117 2008 261 295
3. R.A. Lange, and L.D. Hillis Antiplatelet therapy for ischemic heart disease N Engl J Med 350 2004 277 280 (Pubitemid 38067641)
4. D. Sibbing, S. Braun, and T. Morath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
5. P.A. Gurbel, K.P. Bliden, and B.L. Hiatt Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913 (Pubitemid 36736631)
6. C. Patrono, C. Baigent, and J. Hirsh Antiplatelet drugs: American College of chest physicians evidence-based clinical practice guidelines (8th ed.) Chest 133 2008 199S 233S (Pubitemid 351894914)
7. D. Sibbing, S. Braun, and S. Jawansky Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment Thromb Haemost 99 2008 121 126
8. S.S. Brar, J. ten Berg, and R. Marcucci Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data J Am Coll Cardiol 58 2011 1945 1954
9. P.A. Gurbel, and U.S. Tantry Clopidogrel resistance? Thromb Res 120 2007 311 321 (Pubitemid 46881255)
10. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
11. D.J. Angiolillo, E. Bernardo, and M. Sabate Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease J Am Coll Cardiol 50 2007 1541 1547 (Pubitemid 47532327)
12. S.D. Kim, W. Kang, and H.W. Lee Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects Clin Ther 31 2009 793 803
13. H. Neubauer, J.C. Kruger, and S. Lask Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study Clin Res Cardiol 98 2009 533 540
14. J.T. Brandt, C.D. Payne, and S.D. Wiviott A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 66 2007 e9 e16
15. O.O. Braun, M. Johnell, and C. Varenhorst Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease Thromb Haemost 100 2008 626 633
16. T. Jernberg, C.D. Payne, and K.J. Winters Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173